Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Generate Biomedicines, Inc.GENB · Entity 1553 | Director | February 26, 2026 | March 02, 2026 |
| Moderna, Inc.MRNA · Entity 2025 | Director · Chief Executive Officer | August 05, 2026 | August 07, 2026 |
| Syros Pharmaceuticals, Inc.SYRS · Entity 85437 | Director | September 15, 2016 | September 19, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Generate Biomedicines, Inc.
Report date February 26, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy OCHA LLC | 724,160 |
Reported balance
After 2026-03-02 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-03-02 · Conversion · Acquired 724,160 · Balance 724,160 F1: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Series A Preferred Stock had no expiration date. F2: Shares held by OCHA LLC, of which the Reporting Person is the controlling unit holder and sole managing member. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-02-25 | Direct | 29,561 |
Reported balance
After 2026-02-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-26 · Grant · Acquired 29,561 · Balance 29,561 F3: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy OCHA LLC | 0 |
Reported balance
After 2026-03-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-02 · Conversion · Disposed 1,100,000 · Balance 0 F1: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Series A Preferred Stock had no expiration date. F2: Shares held by OCHA LLC, of which the Reporting Person is the controlling unit holder and sole managing member. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 460,829 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 460,829 |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Series A Preferred Stock had no expiration date.
F2: Shares held by OCHA LLC, of which the Reporting Person is the controlling unit holder and sole managing member. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F3: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.
Moderna, Inc.
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,440,260 |
Ending reported balance
After 2026-08-06 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-08-05 · Exercise / conversion · Acquired 499,246 · Balance 6,687,037 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. Row 2 · 2026-08-05 · Sale · Disposed 147,473 · Balance 6,539,564 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.58 to $56.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 3 · 2026-08-05 · Sale · Disposed 124,838 · Balance 6,414,726 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.59 to $57.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 4 · 2026-08-05 · Sale · Disposed 39,891 · Balance 6,374,835 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.60 to $58.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 5 · 2026-08-05 · Sale · Disposed 187,044 · Balance 6,187,791 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.61 to $59.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 6 · 2026-08-06 · Exercise / conversion · Acquired 252,469 · Balance 6,440,260 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.15 · Expires 2026-08-10 | Direct | 187,541 |
Reported balance
After 2026-08-05 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-05 · Exercise / conversion · Disposed 370,853 · Balance 187,541 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F8: This option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.15 · Expires 2026-08-10 | Direct | 64,928 |
Reported balance
After 2026-08-05 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-05 · Exercise / conversion · Disposed 128,393 · Balance 64,928 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F8: This option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.15 · Expires 2026-08-10 | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-08-06 · Exercise / conversion · Disposed 187,541 · Balance 0 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F8: This option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.15 · Expires 2026-08-10 | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-08-06 · Exercise / conversion · Disposed 64,928 · Balance 0 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F8: This option is fully vested and exercisable. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 9,210,686 |
Reported balance
Holding disclosure · report date 2026-08-05 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 9,210,686 F6: These shares are owned directly by Boston Biotech Ventures. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,564,880 |
Reported balance
Holding disclosure · report date 2026-08-05 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 6,564,880 F7: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.58 to $56.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.59 to $57.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.60 to $58.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.61 to $59.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6: These shares are owned directly by Boston Biotech Ventures. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F7: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F8: This option is fully vested and exercisable.
Syros Pharmaceuticals, Inc.
Report date September 15, 2016 · Filed September 19, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.59 · Expires 2026-09-14 | Direct | 22,000 |
Reported balance
After 2016-09-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-09-15 · Grant · Acquired 22,000 · Balance 22,000 F1: The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments of 2.77% of the shares underlying the award until the third anniversary of the date of the award, subject to Mr. Bancel's continued service as a director through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments of 2.77% of the shares underlying the award until the third anniversary of the date of the award, subject to Mr. Bancel's continued service as a director through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2020 Filed Mar 3, 2020 21:53 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 459 | $25.65 | $11,773.35 |
DisclosureSEC source: 0001127602-20-009078 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 719,456 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.31 to $25.79. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:53 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,463 | $23.48 | $128,271.24 |
DisclosureSEC source: 0001127602-20-009078 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 719,915 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.10 to $24.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:53 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 3,674 | $22.78 | $83,693.72 |
DisclosureSEC source: 0001127602-20-009078 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 725,378 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.09 to $23.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:09 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,286 | $23.00 | $121,578.00 |
DisclosureSEC source: 0001127602-20-008173 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,722,648 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:03 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 11,046 | $18.16 | $200,595.36 |
DisclosureSEC source: 0001127602-20-007170 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 729,052 F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.96 to $18.48. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F6 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 21:03 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,643 | $18.86 | $49,846.98 |
DisclosureSEC source: 0001127602-20-007170 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,232,886 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F3 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 21:03 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,643 | $18.86 | $49,846.98 |
DisclosureSEC source: 0001127602-20-007170 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,953,216 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The Reporting Person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| February 18, 2020 Filed Feb 18, 2020 21:07 UTC | Moderna, Inc. MRNA · Entity 2025 | GiftCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-006014 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,727,934 F4 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The reported disposition represents a bona fide charitable gift made by the reporting person. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 21:07 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 11,046 | $19.02 | $210,094.92 |
DisclosureSEC source: 0001127602-20-006014 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 740,098 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.86 to $19.23. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 02:51 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 4,303 | $23.50 | $101,120.50 |
DisclosureSEC source: 0001127602-20-004985 · form4.xml · nonDerivative · entry 7 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,235,529 F6 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F8 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 02:51 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 8,606 | $23.50 | $202,241.00 |
DisclosureSEC source: 0001127602-20-004985 · form4.xml · nonDerivative · entry 6 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,955,859 F6 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F7 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The Reporting Person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 02:51 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 4,303 | $23.50 | $101,120.50 |
DisclosureSEC source: 0001127602-20-004985 · form4.xml · nonDerivative · entry 5 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,732,934 F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 02:51 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,780 | $22.92 | $40,797.60 |
DisclosureSEC source: 0001127602-20-004985 · form4.xml · nonDerivative · entry 4 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 751,144 F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.31 to $23.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 02:51 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 800 | $21.75 | $17,400.00 |
DisclosureSEC source: 0001127602-20-004985 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 752,924 F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.25 to $22.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 02:51 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 8,466 | $20.76 | $175,754.16 |
DisclosureSEC source: 0001127602-20-004985 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 753,724 F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.19 to $21.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 02:51 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 4,876 | $23.00 | $112,148.00 |
DisclosureSEC source: 0001127602-20-004985 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,737,237 F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:09 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,438 | $20.66 | $50,369.08 |
DisclosureSEC source: 0001127602-20-003493 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,239,832 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F3 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:09 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,438 | $20.66 | $50,369.08 |
DisclosureSEC source: 0001127602-20-003493 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,964,465 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| January 31, 2020 Filed Feb 3, 2020 21:30 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 100 | $21.16 | $2,116.00 |
DisclosureSEC source: 0001127602-20-003163 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 762,190 F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| January 31, 2020 Filed Feb 3, 2020 21:30 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 10,946 | $20.42 | $223,517.32 |
DisclosureSEC source: 0001127602-20-003163 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 762,290 F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.08 to $20.89. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| January 24, 2020 Filed Jan 27, 2020 21:03 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 11,046 | $21.22 | $234,396.12 |
DisclosureSEC source: 0001127602-20-002430 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 773,236 F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.95 to $21.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| January 22, 2020 Filed Jan 23, 2020 21:17 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 15,398 | $23.00 | $354,154.00 |
DisclosureSEC source: 0001127602-20-002273 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,742,113 F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. Read SEC document |
| January 21, 2020 Filed Jan 22, 2020 21:09 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,425 | $20.79 | $50,415.75 |
DisclosureSEC source: 0001127602-20-002157 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,242,270 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F3 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| January 21, 2020 Filed Jan 22, 2020 21:09 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,425 | $20.79 | $50,415.75 |
DisclosureSEC source: 0001127602-20-002157 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,966,903 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| January 17, 2020 Filed Jan 21, 2020 21:15 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 11,046 | $20.96 | $231,524.16 |
DisclosureSEC source: 0001127602-20-002079 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 784,282 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.56 to $21.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 21:12 UTC | Moderna, Inc. MRNA · Entity 2025 | GiftCommon Stock | 4,989 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-001926 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,757,511 F1 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The reported disposition represents a bona fide charitable gift made by the reporting person. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 22:23 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,718 | $21.00 | $57,078.00 |
DisclosureSEC source: 0001127602-20-001573 · form4.xml · nonDerivative · entry 4 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,244,695 F8 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F9 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 22:23 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,718 | $21.00 | $57,078.00 |
DisclosureSEC source: 0001127602-20-001573 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,969,328 F6 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F7 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The Reporting Person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 22:23 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 3,400 | $20.46 | $69,564.00 |
DisclosureSEC source: 0001127602-20-001573 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 795,328 F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.10 to $20.87. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 22:23 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 7,646 | $19.60 | $149,861.60 |
DisclosureSEC source: 0001127602-20-001573 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 798,728 F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.08 to $20.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 11,046 | $19.04 | $210,315.84 |
DisclosureSEC source: 0001127602-20-001119 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 806,374 F5 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.79 and $19.31. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F7 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,557 | $19.57 | $50,040.49 |
DisclosureSEC source: 0001127602-20-001119 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,247,413 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F4 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,557 | $19.57 | $50,040.49 |
DisclosureSEC source: 0001127602-20-001119 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,972,046 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The Reporting Person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| December 27, 2019 Filed Jan 3, 2020 21:03 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 11,046 | $19.53 | $215,728.38 |
DisclosureSEC source: 0001127602-20-000607 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 817,420 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.26 to $19.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| December 20, 2019 Filed Dec 23, 2019 21:31 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 11,046 | $19.69 | $217,495.74 |
DisclosureSEC source: 0001127602-19-035757 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 828,466 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.20 to $19.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 21:46 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 11,046 | $18.53 | $204,682.38 |
DisclosureSEC source: 0001127602-19-035076 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 839,512 F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.35 to $18.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| December 09, 2019 Filed Dec 12, 2019 01:08 UTC | Moderna, Inc. MRNA · Entity 2025 | OtherCommon Stock | 42,132 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-034852 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,762,500 F1 · kind: Represents the receipt of shares by the reporting person pursuant to pro rata distributions-in-kind, without consideration, of shares of the company's common stock effected on December 9, 2019 by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") to the partners of Flagship Fund IV and by its general partner, Flagship Ventures Fund IV General Partner, LLC. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 06, 2019 Filed Dec 10, 2019 00:09 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 200 | $20.95 | $4,190.00 |
DisclosureSEC source: 0001127602-19-034618 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 850,558 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.93 to $20.97. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| December 06, 2019 Filed Dec 10, 2019 00:09 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 6,200 | $20.43 | $126,666.00 |
DisclosureSEC source: 0001127602-19-034618 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 850,758 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.92 to 20.85. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| December 06, 2019 Filed Dec 10, 2019 00:09 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 4,646 | $19.42 | $90,225.32 |
DisclosureSEC source: 0001127602-19-034618 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 856,958 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.88 to $19.87. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 12:02 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 11,046 | $20.54 | $226,884.84 |
DisclosureSEC source: 0001127602-19-034027 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 861,604 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.31 to $20.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| November 22, 2019 Filed Nov 25, 2019 21:08 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 11,046 | $20.48 | $226,222.08 |
DisclosureSEC source: 0001127602-19-033671 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 872,650 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:43 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 336 | $19.38 | $6,511.68 |
DisclosureSEC source: 0001127602-19-033233 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 883,696 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.37 to $19.43. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:43 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 10,710 | $19.02 | $203,704.20 |
DisclosureSEC source: 0001127602-19-033233 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 884,032 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.36 to $19.36. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 12:06 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 11,046 | $17.38 | $191,979.48 |
DisclosureSEC source: 0001127602-19-032406 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 894,742 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.19 to $17.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:39 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 4,500 | $16.68 | $75,060.00 |
DisclosureSEC source: 0001127602-19-031912 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 905,788 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.56 to $16.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:39 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 6,546 | $15.66 | $102,510.36 |
DisclosureSEC source: 0001127602-19-031912 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 910,288 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.62 to $15.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 21:37 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 593,592 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-19-010860 · form4.xml · derivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,592 Underlying: Common Stock · 593,592 shares Expires 2029-03-08 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 21:19 UTC | Moderna, Inc. MRNA · Entity 2025 | ConversionSeries G Preferred Stock · Derivative | 22,935 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030858 · doc4.xml · derivative · entry 16 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 22,935 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: The Series G Preferred Stock converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Series G Preferred Stock had no expiration date. F9 · price: The Series G Preferred Stock converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Series G Preferred Stock had no expiration date. F9 · derivative.exercise_date: The Series G Preferred Stock converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Series G Preferred Stock had no expiration date. F9 · derivative.expiration_date: The Series G Preferred Stock converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Series G Preferred Stock had no expiration date. F2 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 21:19 UTC | Moderna, Inc. MRNA · Entity 2025 | ConversionSeries F Preferred Stock · Derivative | 4,587 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030858 · doc4.xml · derivative · entry 15 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 4,587 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: The Series F Preferred Stock converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Series F Preferred Stock had no expiration date. F8 · price: The Series F Preferred Stock converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Series F Preferred Stock had no expiration date. F8 · derivative.exercise_date: The Series F Preferred Stock converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Series F Preferred Stock had no expiration date. F8 · derivative.expiration_date: The Series F Preferred Stock converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Series F Preferred Stock had no expiration date. F4 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.